| Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer JR Cantor, V Panayiotou, G Agnello, G Georgiou, EM Stone Methods in enzymology 502, 291-319, 2012 | 64 | 2012 |
| Ca2+ Homeostasis Modulation Enhances the Amenability of L444P Glucosylcerebrosidase to Proteostasis Regulation in Patient-Derived Fibroblasts F Wang, G Agnello, N Sotolongo, L Segatori ACS chemical biology 6 (2), 158-168, 2011 | 35 | 2011 |
| Uncoupling intramolecular processing and substrate hydrolysis in the N-terminal nucleophile hydrolase hASRGL1 by circular permutation W Li, JR Cantor, SD Yogesha, S Yang, L Chantranupong, JQ Liu, ... ACS chemical biology 7 (11), 1840-1847, 2012 | 28 | 2012 |
| Discovery of a substrate selectivity motif in amino acid decarboxylases unveils a taurine biosynthesis pathway in prokaryotes G Agnello, LL Chang, CM Lamb, G Georgiou, EM Stone ACS chemical biology 8 (10), 2264-2271, 2013 | 26 | 2013 |
| A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration P Biswas, VRM Chavali, G Agnello, E Stone, C Chakarova, JL Duncan, ... Human molecular genetics 25 (12), 2483-2497, 2016 | 21 | 2016 |
| Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1 G Agnello, SE Alters, SW Rowlinson Translational Research 217, 11-22, 2020 | 17 | 2020 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| Arginase therapy combines effectively with immune checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth MD Badeaux, AS Rolig, G Agnello, D Enzler, MJ Kasiewicz, L Priddy, ... Cancer Immunology Research 9 (4), 415-429, 2021 | 11 | 2021 |
| GFP reporter screens for the engineering of amino acid degrading enzymes from libraries expressed in bacteria O Paley, G Agnello, J Cantor, TH Yoo, G Georgiou, E Stone Enzyme Engineering: Methods and Protocols, 31-44, 2013 | 6 | 2013 |
| reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and … G Agnello, SE Alters, DG Lowe, SW Rowlinson Cancer Research 77 (13_Supplement), 3964-3964, 2017 | 3 | 2017 |
| Development of AEB1102, an engineered human arginase 1 for patients with solid tumors SW Rowlinson, SE Alters, G Agnello, J Tyler, A Lowe, ... Cancer Research 76 (14_Supplement), 1042-1042, 2016 | 3 | 2016 |
| Depletion of blood arginine with pegzilarginase (AEB1102) in combination with anti-PD-L1 increases tumor infiltration by immune cells and enhances antitumor activity G Agnello, MD Badeaux, D Enzler, L Priddy, JF Wiggins, CL Daige, ... Cancer Research 78 (13_Supplement), 869-869, 2018 | 2 | 2018 |
| Depleting blood arginine with AEB1102 (Pegzilarginase) exerts additive anti-tumor and synergistic survival benefits when combined with immunomodulators of the PD-1 pathway G Agnello, M Badeaux, S Alters, D Lowe, S Rowlinson JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017 | 2 | 2017 |
| Engineering of the recombinant expression and PEGylation efficiency of the therapeutic enzyme human thymidine phosphorylase CS Karamitros, CM Somody, G Agnello, S Rowlinson Frontiers in Bioengineering and Biotechnology 9, 793985, 2021 | 1 | 2021 |
| Abstract CT164: Phase 1a/1b clinical trial of LP-284, a highly potent TP53 mutation agnostic DNA damaging agent, in patients with refractory or relapsed lymphomas and solid … J Zhou, R Ewesuedo, G Agnello, A Kulkarni, K Bhatia Cancer Research 84 (7_Supplement), CT164-CT164, 2024 | | 2024 |
| Kompozicije i postupci lečenja karcinoma pomoću deplecije arginina i imunoonkološkh agenasa D Lowe, SW Rowlinson, S Alters, G Agnello | | 2022 |
| Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler D Lowe, SW Rowlinson, S Alters, G Agnello | | 2022 |
| Erratum: Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase (vol 10, 878674, 2022) CS Karamitros, CM Somody, G Agnello, S Rowlinson FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY 10, 2022 | | 2022 |
| Compositions and Methods for Treating Cancer with Arginine Depletion and Immuno Oncology Agents D Lowe, SW Rowlinson, S Alters, G Agnello US Patent App. 16/983,635, 2020 | | 2020 |
| Compositions and methods for treating cancer with arginine depletion and immuno oncology agents D Lowe, SW Rowlinson, S Alters, G Agnello US Patent 10,729,752, 2020 | | 2020 |
George GeorgiouUniversity of Texas at AustinVerified email at che.utexas.edu
